AA
LEGN icon

ALPS Advisors’s Legend Biotech LEGN Stock Holding History

ALPS Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-177,274
Closed -$8.96M – 937
2021
Q3 		$8.96M Sell
177,274
-523
-0.3% -$21.8K 0.09% 151
2021
Q2 		$7.3M Sell
177,797
-61,033
-26% -$2.07M 0.06% 157
2021
Q1 		$6.93M Buy
238,830
+228
+0.1% +$6.22K 0.07% 156
2020
Q4 		$6.72M Buy
+238,602
New +$6.87M 0.08% 161

Other funds holding LEGN

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

ALPS Advisors's LEGN Position: Q4 2021 in Review

ALPS Advisors sold out of Legend Biotech (LEGN) in Q4 2021, closing a stake of 177,274 shares — an estimated $8.96M sold.

ALPS Advisors first reported a position in LEGN in Q4 2020 and held it in 4 quarters. The position peaked at $8.96M in Q3 2021. 139 funds tracked by Wall St. Rank hold LEGN as of Q4 2021.

  • ALPS Advisors reported no remaining Legend Biotech position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 177,274 Legend Biotech shares in Q4 2021, an estimated $8.96M.
  • ALPS Advisors first reported a position in Legend Biotech in Q4 2020 and held it in 4 quarters.
  • ALPS Advisors's Legend Biotech position peaked at $8.96M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.